by OBM Transplantation Editorial Office

Received: 04 January 2023;  Published: 04 January 2023;  doi: 10.21926/obm.transplant.2301172

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2022. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal’s editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers receive a voucher entitling them to a discount on their next LIDSEN publication and can download a certificate of recognition [...]

by Braulio A. Marfil-Garza  and Tatsuya Kin

Received: 11 December 2022;  Published: 19 December 2022;  doi: 10.21926/obm.transplant.2204171

by Alma Rechnitzer  , Richard Teo  , Abigail Brooks  , Juan P. Rocca  , Nidal A. Mudhi  , Julia Torabi  , Maria Ajaimy  , Luz Liriano-Ward  , Yorg Azzi  , Cindy Pynadath  , Pablo Loarte-Campos  , Enver Akalin  , Marie E. Le  , Milan M. Kinkhabwala  and Jay A. Graham

Received: 06 September 2022;  Published: 21 November 2022;  doi: 10.21926/obm.transplant.2204170

The 2014 Pancreas Allocation System established national qualifying criteria for simultaneous kidney pancreas (SPK) transplantation. The 2019 UNOS Pancreas Transplantation Committee Policy 11.3.B modified these guidelines to expand transplantation. Subsequent effects on recipient demographics have not been studied. We analyzed 81 SPK transplantations performed at our center from June 2014 to December 2020 to compare recipient demographics and outcomes before and after the 11.3.B policy change. National data were al [...]

by Katarina Tomulic Brusich

Received: 30 August 2022;  Published: 15 November 2022;  doi: 10.21926/obm.transplant.2204169

Transplantation is a widely accepted and successful life-saving treatment for hundreds of thousands of patients. However, transplant medicine still faces a number of obstacles. One of the most significant is the large disparity between the number of donors and recipients and the growing need for re-transplantation. In the last two decades, the improvement and organization of the national transplantation program in Croatia have resulted in a steadily increasing donor rate and therefore the transplantation numbers. A [...]

by Ana Paula Leopercio  , Christini Emori  , Elisabete Calore Neiva  , Ana Lucia Silva Souza  , Ana Cristina Amaral  , Gustavo Almeida Vieira  , Raimundo Araujo Gama  , Jose Osmar Medina-Pestana  and Maria Lúcia Ferraz

Received: 22 June 2022;  Published: 26 October 2022;  doi: 10.21926/obm.transplant.2204168

Hepatitis B virus (HBV) infection is frequent among patients with chronic kidney disease (CKD). HBV reactivation after kidney transplant (KT) is more common in patients with HBsAg+; however, it can also occur in previously infected individuals, particularly those with HBsAg negative and total antiHBc positive (HBsAg-/antiHBcT+). However, reactivation in this population has scarce and conflicting data. This study aimed to assess the reactivation risk in KT recipients with previous HBV infection (antiHBcT+). A retros [...]

by OBM Transplantation Editorial Office

Received: 09 October 2022;  Published: 17 October 2022;  doi: 10.21926/obm.transplant.2204167

by Nicholas J. Geraghty  , Amal Elhage  , Peter Cuthbertson  , Debbie Watson  and Ronald Sluyter

Received: 06 June 2022;  Published: 06 September 2022;  doi: 10.21926/obm.transplant.2203166

Allogeneic hematopoietic stem cell transplantation is a curative therapy for hematological malignancies, but its efficacy is limited by graft-versus-host disease (GVHD). This life-threatening disorder develops when donor (graft) immune cells cause inflammatory damage to recipient (host) tissues. The immune cell receptor channel P2X7 and its ligand adenosine 5’-triphosphate (ATP) have been implicated in GVHD pathogenesis. Therefore, this signaling axis represents a potential therapeutic target. This study aimed to i [...]

by Kurumi Taniguchi  , Haruka Sawamura  , Yuka Ikeda  , Ai Tsuji  and Satoru Matsuda

Received: 02 May 2022;  Published: 30 August 2022;  doi: 10.21926/obm.transplant.2203165

Hematopoietic stem cell transplantation (HSCT) is a standard form of cellular therapy for patients suffering from malignant hematological diseases. However, graft-versus-host disease (GVHD) is a very serious complication and a major cause of morbidity and mortality after allogeneic HSCT. Calcineurin inhibitors, such as cyclosporine, are widely used to enhance the survival of patients who have undergone HSCT. Unfortunately, both GVHD and cyclosporine occasionally cause nephropathy. Several studies have shown that th [...]

by Ginevra G Adamo  , Sergio D'Angelo  , Angeli Christy Yu  , Marco Pellegrini  , Federico Bernabei  , Vincenzo Scorcia  and Giuseppe Giannaccare

Received: 17 June 2022;  Published: 02 August 2022;  doi: 10.21926/obm.transplant.2203164

Graft-versus-host disease (GVHD) is a serious complication that may occur in patients receiving allogeneic hematopoietic stem cell transplant (HSCT). GVHD occurs because of the immunological reaction between the donor’s T cells and the recipient’s antigens; GVHD may develop in different tissues, including the eye. Corneal perforation is an uncommon but vision-threatening manifestation of GVHD. We reported the case of a 65-year-old male patient who developed corneal perforation sequentially in both eyes 3 years afte [...]

by Ibrahim El-Serafi  , Sandra Oerther  , Ying Zhao  and Moustapha Hassan

Received: 08 July 2022;  Published: 27 July 2022;  doi: 10.21926/obm.transplant.2203163

Cytochrome P450 2J2 (CYP2J2) is one of the recently discovered enzymes that is involved in the metabolism of several drugs. It is mainly an extrahepatic enzyme which can, to some extent, explain some the drugs’ side effects such as cyclophosphamide (Cy). Cyclophosphamide is an alkylating agent that is commonly used in conditioning prior to stem cell transplantation. It is a prodrug that is bio-activated by several CYPs including CYP2J2. Cy is known to have several side effects and its extrahepatic activation by CYP [...]